Breast, colorectal and gastric cancers affect approximately 3 million people and kill over 1,6 million patients each year worldwide [1]. Primary prevention is obviously the most promising research strategy to save the lives of these patients. Although Effective chemoprevention drugs have been developed as tamoxifen for the prevention of women with a moderate or high risk of breast cancer [2] and aspirin or COX-2 inhibitors for the prevention of colorectal cancer [3 they are not in wide clinical use because if their adverse effects in health individuals and for various other reasons [2,3]
